Sept 17 (Reuters) - Eli Lilly ( LLY ) plans to file for

approval of its experimental weight-loss pill orforglipron with

regulators in the United States, Britain, European Union, Japan

and China "within weeks" of each other, its international

president Patrik Jonsson told Reuters.

"We are submitting to most of the major regulatory bodies

pretty much at the same time," he said.

Jonsson added that applications would also go to regulators

in the United Arab Emirates and Saudi Arabia. The coordinated

filings come as the company seeks to extend its lead in the

global weight-loss drug market against rival Novo Nordisk